Cite
Lorenzi M, Ferro A, Cecere F, et al. First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study. Oncologist. 2021;doi: 10.1002/onco.13951.
Lorenzi, M., Ferro, A., Cecere, F., Scattolin, D., Del Conte, A., Follador, A., Pilotto, S., Polo, V., Santarpia, M., Chiari, R., Pavan, A., Maso, A. D., Da Ros, V., Targato, G., Vari, S., Indraccolo, S., Calabrese, F., Frega, S., Bonanno, L., Conte, P. F., Guarneri, V., & Pasello, G. (2021). First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study. The oncologist, . https://doi.org/10.1002/onco.13951
Lorenzi, Martina, et al. "First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study." The oncologist vol. (2021). doi: https://doi.org/10.1002/onco.13951
Lorenzi M, Ferro A, Cecere F, Scattolin D, Del Conte A, Follador A, Pilotto S, Polo V, Santarpia M, Chiari R, Pavan A, Maso AD, Da Ros V, Targato G, Vari S, Indraccolo S, Calabrese F, Frega S, Bonanno L, Conte PF, Guarneri V, Pasello G. First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study. Oncologist. 2021 Aug 23; doi: 10.1002/onco.13951. Epub 2021 Aug 23. PMID: 34424565.
Copy
Download .nbib